Tirzepatide 5/10 mg

Tirzepatide 5/10 mg is a dual-action injectable medication that targets both GLP-1 and GIP receptors to support effective weight loss and blood-sugar management. It helps reduce appetite, improves metabolic response, and enhances fat-burning efficiency. Commonly used in Type 2 diabetes treatment and medical weight-loss programs, it offers significant results when taken consistently. The dosage is usually increased gradually under medical supervision for safe and optimal outcomes.

It is primarily used for Type 2 diabetes management and medically supervised weight loss. It helps regulate blood sugar levels and reduces food cravings.

Description

Composition

Each pack contains:

  • One vial with Tirzepatide – 5–10 mg (Dual GIP and GLP-1 receptor agonist)
  • One ampoule with 2 ml sterile water for injection

Pharmacological Effects

  • Dual GIP & GLP-1 receptor agonism: Enhances insulin secretion and improves glycemic control.
  • Glucagon suppression: Reduces hepatic glucose output.
  • Appetite suppression & delayed gastric emptying: Promotes satiety and aids in weight reduction.
  • Superior HbA1c reduction: More effective than GLP-1–only agonists (e.g., semaglutide).

Indications

  • Type 2 Diabetes:
    • Weekly dose escalation: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 15 mg over 20 weeks.
  • Chronic Weight Management:
    • Weekly escalation: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.

Recommended Dose

Reconstitution

  • Add 1 mL bacteriostatic water → yields a 5 mg/mL solution.

Dosing Protocol

  • Weeks 1–4: 2.5 mg weekly (0.5 mL of 5 mg/mL).
  • Weeks 5–8: 5 mg weekly (1 mL).
  • Titration: Increase by 2.5 mg every 4 weeks (up to a maximum of 15 mg weekly).
  • Maintenance: 5–15 mg weekly depending on tolerance and therapeutic goals.

Side Effects

Common (≥10%)

  • Nausea, vomiting, diarrhea, constipation.
  • Loss of appetite.

Less Common

  • Hypoglycemia (more likely with insulin or sulfonylureas).
  • Gallbladder issues (e.g., cholelithiasis).
  • Injection-site redness or itching.

Contraindication

  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome.
  • Pregnancy (insufficient safety data).
  • Severe gastrointestinal disease (e.g., gastroparesis).
  • Hypersensitivity to GIP/GLP-1 receptor agonists.

Storage Conditions

  • Unreconstituted powder: Refrigerate at 2–8°C (stable until expiration). Do not freeze.
  • Reconstituted solution: Store at 2–8°C and use within 30 days (with bacteriostatic water).
  • Manufactured pens (Mounjaro / Zepbound):
    • Unopened: Refrigerate at 2–8°C.
    • In use: May be stored at room temperature (≤30°C) for up to 21 days.

Disclaimer: This product is not for human use. It is intended for laboratory research only. Not for diagnostic, therapeutic, or veterinary purposes. Buyer assumes all responsibility for proper handling and legal compliance. Keep out of reach of children. Not for consumption.

Reviews

There are no reviews yet.

Be the first to review “Tirzepatide 5/10 mg”

Your email address will not be published. Required fields are marked *